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Abstract
Introduction: We have previously reported that bacterial toxins, especially endotoxins such as lipopolysaccharides
(LPS), might be important causative agents in the pathogenesis of rheumatoid arthritis (RA) in an in vitro model
that simulates the potential effects of residing in damp buildings. Since numerous inflammatory processes are
linked with the nuclear factor-B (NF-B), we investigated in detail the effects of LPS on the NF-B pathway and
the postulated formation of procollagen-endotoxin complexes.
Methods: An in vitro model of human chondrocytes was used to investigate LPS-mediated inflammatory signaling.
Results: Immunoelectron microscopy revealed that LPS physically interact with collagen type II in the extracellular
matrix (ECM) and anti-collagen type II significantly reduced this interaction. BMS-345541 (a specific inhibitor of IB
kinase (IKK)) or wortmannin (a specific inhibitor of phosphatidylinositol 3-kinase (PI-3K)) inhibited the LPS-induced
degradation of the ECM and apoptosis in chondrocytes. This effect was completely inhibited by combining BMS-
345541 and wortmannin. Furthermore, BMS-345541 and/or wortmannin suppressed the LPS-induced upregulation
of catabolic enzymes that mediate ECM degradation (matrix metalloproteinases-9, -13), cyclooxygenase-2 and
apoptosis (activated caspase-3). These proteins are regulated by NF-B, suggesting that the NF-B and PI-3K
pathways are involved in LPS-induced cartilage degradation. The induction of NF-B correlated with activation of
IBa kinase, IBa phosphorylation, IBa degradation, p65 phosphorylation and p65 nuclear translocation. Further
upstream, LPS induced the expression of Toll-like receptor 4 (TLR4) and bound with TLR4, indicating that LPS acts
through TLR4.
Conclusion: These results suggest that molecular associations between LPS/TLR4/collagen type II in chondrocytes
upregulate the NF-B and PI-3K signaling pathways and activate proinflammatory activity.
Introduction
Rheumatoid arthritis (RA) is a systemic and chronic
inflammatory disease that occurs in 0.5 to 1.0% of the
adult population worldwide [1]. It is characterized by
hyperplasia of the synovial lining cells, increase in
macrophages, high levels of proinflammatory cytokines,
such as IL-1b and TNF-a, expression of autoantibodies
and upregulation of catabolic matrix degrading enzymes
such as matrix metalloproteinases (MMPs), and serine
proteases leading to progressive destruction of cartilage
and bone [2-4]. RA can lead to joint and cartilage
damage, significant disability, and reduction in quality of
life. RA is a multifactorial disease and classified as an
autoimmune disorder, that primarily affects the small
diarthrodial joints of the hands and feet and affects mul-
tiple joints throughout the body [5]. Although the etiol-
ogy of RA is not yet fully understood [6], it is believed
to be caused by a combination of environmental (micro-
bial and viral triggers), immunomodulatory, genetic pre-
disposition factors and a number of inflammatory
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pathways in response to endogenous and/or exogenous
antigens [7]. These factors play essential roles in the
pathogenesis of RA.
A prominent feature of RA is the T-cell infiltrates that
suggest these cells are key participants in RA [8,9].
Moreover, macrophage-like and fibroblast-like synovio-
cytes proliferate and form a pannus, which destroys car-
tilage and subchondral bone leading to loss of joint
function [10]. Activated macrophages and synoviocytes
produce soluble mediators and proinflammatory cyto-
kines including TNF-a and IL-1b, which play a major
role during RA, directing upregulation of other proin-
flammatory cytokines, increasing synovial cellular infil-
tration, macrophages, osteoclast and chondrocyte
activation and increasing angiogenesis [11,12].
It is known that lipopolysaccharides (LPS) are the
main endotoxin components of gram-negative bacterial
cell walls. They activate immune cells, such as macro-
phages and neutrophils in the host and in turn, the sti-
mulated cells synthesize proinflammatory factors, such
as IL-1b and TNF-a, matrix proteases and free radicals
and thus lead to dramatic secondary inflammation in
tissues [13,14]. Further, LPS is used to establish transi-
ent synovitis-osteoarthritis models for therapeutic
research [15]. LPS-induced signaling is thought to begin
with its binding to specific surface receptors such as
Toll-like receptor 4 (TLR4), which trigger intracellular
signaling cascades leading to activation of the multiple
proinflammatory signaling pathways [16,17]. Moreover,
LPS is the primary ligand of TLR4, activating it through
binding to its accessory protein MD-2 [18].
It has been previously suggested that the inhabitants
of buildings with microbiological infestation caused by
dampness through, for example, water damage have an
increased risk of RA [19-21]. We also observed a con-
nection between microbial infestation of buildings after
water damage and RA manifestation in inhabitants [19],
where symptoms of RA decreased in patients after
removing damp walls, with 26% of patients completely
recovered [19]. In a previous in vitro study, we have
demonstrated that in primary isolated chondrocytes,
bacterial endotoxins respectively LPS from damp walls
in buildings, dose-dependently increased MMP-3 pro-
duction and dramatically suppressed collagen type II
production [19].
Several lines of evidence suggested that proinflamma-
tory cytokines and LPS stimulate multiple signaling
pathways such as the phosphatidylinositol 3-kinase (PI-
3K)/protein kinase B (Akt), mitogen-activated protein
kinase (MAPK) and nuclear factor-B (NF-B) [22,23].
Several reports have suggested that PI-3Ks are involved
in the cytokine signaling pathways and inflammatory
processes and mediate activation and translocation of
NF-B through targeting IB kinase (IKK)-a kinase or
phosphorylation of p65, a process that is inhibited by
the PI-3K-specific inhibitor wortmannin [24,25]. PI-3K
activates Akt one of the main downstream kinases in
different cells [26]. Furthermore, NF-B is activated in
the synovium in humans and animals, supporting an
essential role for this transcription factor in cartilage
destruction in RA [27,28]. The inhibited subunits of NF-
B are trapped in the cytoplasm as a complex by asso-
ciation with an inhibiting IBa subunit. Through the
phosphorylation, IBa dissociates from the complex and
the p65 and p50 subunits freely translocate to the cell
nucleus and bind to NF-B recognition sites in the pro-
moter regions of various NF-B-regulated genes. Acti-
vated NF-B is known to be involved in the regulation
of a wide array of genes; among them are those in the
infection, adhesion, cell cycle, apoptosis, survival and
inflammatory process by upregulating the transcriptional
levels of multiple genes, including IL-1b, TNF-a, IL-6,
cyclooxygenase-2 (COX-2) and matrix metalloprotei-
nases (MMPs) [29-31]. NF-B appears to be a common
target of multiple converging catabolic signaling path-
ways mediated by proinflammatory cytokines.
Hence, in this study we have investigated in an in
vitro model of human chondrocytes: (1) the presence of
LPS in the extracellular matrix (ECM) in cartilage and
its binding potential to collagen fibrils (procollagen-
endotoxin complex, (PEC)), (2) whether LPS upregulate
the inflammatory effects, which are responsible for
matrix degradation, inflammation and apoptosis and (3)
whether LPS/TLR4 association, at least in part, activates
NF-B and PI-3K/Akt signaling pathways.
Materials and methods
Antibodies
Antibodies against collagen type II (AB746), alkaline
phosphatase-linked sheep anti-mouse and sheep anti-
rabbit secondary antibodies for immunoblotting were
purchased from Millipore (Schwalbach, Germany). Poly-
clonal anti-active caspase-3 and monoclonal MMP-9
and -13 antibodies recognizing both proenzyme and
activated enzyme were obtained from R&D Systems
(Abingdon, UK). Monoclonal anti-b-actin and normal
rabbit IgG were purchased from Sigma-Aldrich Chemie
(Munich, Germany). Antibodies against phospho-specific
IBa (Ser 32/36) and against anti-phospho-specific p65
(Ser536) were obtained from Cell Technology (Beverly,
MA, USA). Anti-IBa kinase (IKK)-a and anti-IKK-b
were obtained from Imgenex (Hamburg, Germany).
Monoclonal (anti-poly (ADP-ribose) polymerase)
(PARP) antibodies were purchased from Becton Dickin-
son (Heidelberg, Germany). Cyclooxygenase-2 antibody
was obtained from Cayman Chemical (Ann Arbor, MI,
USA). Polyclonal antibody against TLR4 was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
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Secondary antibodies for immunofluorescence were pur-
chased from Dianova (Hamburg, Germany). All antibo-
dies were used at concentrations and dilutions
recommended by the manufacturer. Monoclonal anti-
Escherichia coli LPS antibody (2D7/1) was obtained
from Abcam (Cambridge, UK). Polyclonal rabbit anti-E.
coli O6 serum was kindly provided by Prof. P. Roggentin
(Institute für Hygiene und Umwelt, Hamburg, Ger-
many), against E.coli Nissle 1917 (DSM 6601, serotype
O6:K5:H1).
Growth media, chemicals and endotoxin
Growth medium (Ham’s F-12/Dulbecco’s modified
Eagle’s medium (DMEM) (50/50) containing 10% fetal
calf serum (FCS), 25 mg/ml ascorbic acid, 50 IU/ml
streptomycin, 50 IU/ml penicillin, 2.5 mg/ml amphoteri-
cin B, essential amino acids, and L-glutamine) was
obtained from Seromed (Munich, Germany). BMS-
345541 and Trypsin/EDTA (EC 3.4.21.4) were pur-
chased from Sigma-Aldrich. Epon and LR-white were
obtained from Plano (Marburg, Germany). Wortmannin
was purchased from Biomol (Plymouth Meeting, PA,
USA). LPS from E.coli endotoxins (E8029) was pur-
chased from Sigma-Aldrich and dissolved in phosphate-
buffered saline (PBS) at 1 mg/ml.
Experimental design
Based on our observations during the last years, we have
formulated the hypothesis that bacteria or bacterial
metabolites may be important causative agents for rheu-
matic diseases [19]. However, it is not possible to iden-
tify all bacteria in the samples from damp buildings, as
some species will not grow on agar. We further
observed that exercised and constantly used joint areas
are specially affected. Therefore, we assumed that very
fine particles, molecule clusters or molecular aggregates
that are inhaled from the inhabitants would partly be
transported to the joints or the cartilage through circu-
lation. We further hypothesized that endotoxins may
interfere directly with the mechanism for the synthesis
and assembly of collagen fibres.
We performed experiments in this study on primary
human chondrocytes (HCHON) purchased from Provi-
tro (Berlin, Germany), to mimic cellular events that
occur in the clinical condition of osteoarthritis (OA) or
RA. To stimulate inflammatory processes in chondro-
cytes, we adopted a model that stimulates cells with LPS
(0 to 1000 ng/ml). During monolayer expansion chon-
drocytes were cultured in whole-cell culture medium
containing 10% FCS. Chondrocytes were washed three
times with serum-starved medium (containing only 0.5%
FCS) and further incubated for 30 min with the same
medium before initiating treatment with LPS and/or
inhibitors.
In a second approach, chondrocytes in monolayer cul-
tures, treated as above, were transferred to high-density
cultures and cultured under identical conditions with
serum-starved medium to examine the effects of LPS
and/or inhibitors on chondrocyte differentiation poten-
tial in a three-dimensional environment. Three-dimen-
sional high-density culture was performed as previously
described [32]. Briefly, primary cultures of human chon-
drocytes (1 × 106) were pipetted onto a nitrocellulose
filter (pore diameter 0.2 µm, Sartorius, Göttingen, Ger-
many) resting on a steel net bridge. Culture medium
reached the filter medium interface and cells were nur-
tured through diffusion. After one day in culture, cells
aggregated and formed a pellet on the filter. Cultures
were grown at 37°C in a humidified atmosphere with
5% CO2.
For investigation of NF-B translocation and IBa
phosphorylation, human chondrocyte cultures were trea-
ted either with LPS or co-treated with LPS and/or inhibi-
tors for the indicated times and nuclear and cytoplasmic
extracts were prepared. The experiments were performed
in triplicate and the results are provided as mean values
from three independent experiments.
Isolation of human chondrocyte cytoplasmic and nuclear
extracts
Isolation of cytoplasmic and nuclear extracts was per-
formed as previously described in detail [33]. Briefly,
primary human chondrocytes in monolayer cultures
were trypsinized and washed twice in 1 ml ice-cold PBS.
The cell pellet was resuspended in 400 µl hypotonic
lysis buffer containing protease inhibitors and incubated
on ice for 15 min. Some 12.5 µl of 10% NP-40 were
added and the cell suspension vigorously mixed for 15
seconds. The extracts were centrifuged for 1.5 min. The
supernatants (cytoplasmic extracts) were frozen at -70°
C. Approximately 25 µl of ice-cold nuclear extraction
buffer was added to the pellets and incubated for 30
min. Extracts were centrifuged and the supernatant
(nuclear extracts) transferred to pre-chilled tubes for
storage at -70°C.
Western blot analysis and immunoblotting
Immunoblotting was performed as described in detail
by Shakibaei et al. [34,35]. Cell proteins were extracted
with lysis buffer (50 mM Tris/HCl, pH 7.2, 150 mM
NaCl, l% (v/v) Triton X100, 1 mM sodium orthovana-
date, 50 mM sodium pyrophosphate, 100 mM sodium
fluoride, 0.01% (v/v) aprotinin, 4 µg/ml pepstatin A, 10
µg/ml leupeptin, 1 mM phenylmethylsulfonyl-fluoride
(PMSF)) on ice for 30 min. For immunoblotting, the
total proteins were separated by SDS-PAGE on a 10%
SDS-polyacrylamide gel under reducing conditions.
Subsequently, the proteins were transferred for 60 min
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at 120 V onto a nitrocellulose membrane (Schleicher &
Schüll, Dassel, Germany) using a transblot electrophor-
esis apparatus (Mini Trans Blot™, Bio-Rad Labora-
tories, Richmond, CA, USA). The membranes were
then blocked with a blocking buffer, containing 5%
(w/v) skimmed milk powder in PBS/0.1% Tween 20,
overnight at 4°C.
Immunoblotting with primary antibodies was per-
formed for 1 h at room temperature (RT), followed by
three washes in the blocking buffer. Subsequently, incu-
bation with secondary antibody conjugated to alkaline
phosphatase was performed for 30 min at RT. All antibo-
dies were diluted with blocking buffer. After three washes
in blocking buffer and two washes in 0.1 M Tris, pH 9.5,
containing 0.05 M MgCl2 and 0.1 M NaCl, color develop-
ment was performed using nitro blue tetrazolium and
5-bromo-4-chloro-3-indoyl-phosphate (p-toluidine salt)
(Pierce, Rockford, IL, USA) as substrates for alkaline
phosphatase.
Co-immunoprecipitation of LPS and TLR4
Primary human chondrocyte cultures were treated either
with LPS (100 ng/ml) or left untreated overnight. The
medium and unbound LPS were then removed. The
chondrocytes were washed three times and whole-cell
extracts were prepared, immunoprecipitated [34] with
an anti-LPS antibody, and precipitates were subjected to
western blot analysis using an anti-TLR4 antibody.
Immunofluorescence analysis of TLR4 and NF-B
The effect of LPS on TLR4 and NF-B translocation
from the chondrocyte cytoplasm to the nucleus in
response to NF-B-activation by LPS was investigated
by an immunocytochemical method, as previously
described in detail [36]. Briefly, cells were seeded on
glass plates and incubated for 24 h. The cells were
rinsed three times and preincubated for 1 h with serum-
starved medium, and then stimulated with 100 ng/ml
LPS or BMS-345541 (5 mM) alone or prestimulated
with BMS-345541 (5 mM) for 12 h before treating with
LPS (100 ng/ml) for an additional 24 h in serum-starved
medium. Glass plates were rinsed three times in PBS
before methanol fixation and permeabilization of the
cell and nuclear membranes for 1 h at ambient tempera-
ture (AT). Cells were overlaid with protease-free bovine
serum albumin (BSA) for 10 min at AT, rinsed with
PBS and incubated with primary antibodies (TLR4,
phospho p65, 1:30 in PBS/BSA) in a humid chamber
overnight at 4°C. They were gently washed several times
with PBS/BSA before incubation with rhodamine red-
conjugated secondary antibody (diluted 1:50 in PBS) for
1 h at AT and finally washed again three times with
aqua dest. Counterstaining was performed with DAPI to
visualize the cell nuclei. Samples were evaluated under a
light microscope (Leica, Wetzlar, Germany) and photo-
micrographs were digitally stored.
Immune complex kinase assay
To evaluate the effect of endotoxin on IKK activation,
immune complex kinase assays were performed. The
assay was performed as described in detail by Shakibaei
et al. [37]. Briefly, the IKK complex was immunoprecipi-
tated from whole cell lysates with antibodies against
IKK-a and IKK-b and subsequently incubated with pro-
tein A/G-agarose beads (Pierce, Ulm, Germany). After a
2 h incubation, the beads were washed with lysis buffer
and resuspended in a kinase assay solution containing
50 mM HEPES (pH 7.4), 20 mM MgCl2, 2 mM dithio-
threitol, 10 mM unlabeled ATP and 2 mg substrate
GSTIBa (amino acid 1-54) and incubated at 30°C for
30 min. This was followed by boiling in SDS-PAGE
sample buffer for 5 min. The proteins were transferred
to a nitrocellulose membrane after SDS-polyacrylamide
gel electrophoresis under reducing conditions as
described above. Phosphorylation of GST-IBa was
assessed using a specific antibody against phosphospeci-
fic IBa (Ser 32/36). To demonstrate the total amounts
of IKK-a and IKK-b in each sample, whole-cell lysates
were transferred to a nitrocellulose membrane after
SDS-polyacrylamide gel electrophoresis under reducing
conditions as described above.
Transmission electron microscopy (TEM)
A detailed description of the culture technique used for
transmission electron microscopy has been published
[32,36]. After fixation and post fixation in 1% tannic
acid (0.1 M phosphate buffer) and 1% OsO4 solution
(0.1 M phosphate buffer), cartilage high-density cultures
were rinsed and dehydrated in ascending alcohol series.
They were embedded in Epon, cut on a Reichert Ultra-
cut (Leica, Wetzlar, Germany) followed by contrasting
with 2% uranyl acetate/lead citrate. For inspection a
transmission electron microscope (EM 10 Zeiss, Insti-
tute of Pharmacology, Berlin, Germany) was used.
Immunoelectron microscopy
A detailed description of the culture technique used for
immunoelectron microscopy has been published [32,36].
High-density cultures were washed three times in PBS
before fixation in 3% formaldehyde freshly prepared from
paraformaldehyde plus 0.25% glutaraldehyde in PBS for 1
h. Then, the cultures were washed with PBS/1% BSA,
dehydrated in ethanol and embedded in LR-white. Ultra-
thin sections were cut and treated with the following
solutions: (1) 1% BSA at AT for 30 min; (2) testicular
chondroitinase (5000 U/ml) for 5 min at AT to unmask
epitopes; (3) PBS/1% BSA/0.5% Tween 20 2 × 5 min at
AT; (4) primary antibodies (1:50 in PBS/1% BSA/0.5%
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Tween 20) overnight at 4°C; (5) PBS/BSA/Tween for 2 × 5
min at AT; (6) secondary antibodies conjugated with goat
anti-rabbit immunoglobulin with 10 nm gold particles
(1:50 for 30 min) at AT. (7) After rinsing for 2 × 5 min at
AT, (8) contrasting was carried out with 1% tannic acid
for 20 min at AT, with OsO4 for 10 min and with 2% ura-
nyl acetate for 30 min. Finally, the sections were rinsed
and examined under a transmission electron microscope
(TEM 10 Zeiss, Institute of Pharmacology, Berlin,
Germany).
Pharmacological experiments with BMS-345541 or/and
wortmannin
Primary human chondrocytes were grown in growth
medium for 24 h. NF-B or PI-3K inhibition experiments
were carried out in serum-starved medium (0.5% FCS).
Serum-starved chondrocytes were stimulated with LPS
alone (100 ng/ml) or with wortmannin (20 nM), BMS-
345541 (5 mM) or prestimulated with wortmannin (20
nM), BMS-345541 (5 mM) for 12 h before treating with
LPS (10 to 1000 ng/ml) for an additional 24 h. LPS or
inhibitors concentrations used in this study are the same
as those in previous studies from our own laboratory and
were calculated through dose-dependent experiments on
human articular chondrocytes [19]. After these treat-
ments, nuclear extracts were prepared and examined for
NF-B and/or PI3k/Akt as described above.
Results
We examined the effect of endotoxin (LPS) on NF-B
and PI-3K activation pathways and NF-B-regulated
gene expression. The studies were performed on pri-
mary human chondrocytes, as these cells are one of the
primary targets of LPS during inflammatory processes in
rheumatic diseases such as RA.
Presence of LPS (endotoxin) in the cartilage ECM in high-
density culture in vitro
To visualize LPS accumulation in the cartilage matrix,
we established high-density cultures and treated them
with LPS (100 ng/ml) for 3, 5, 7 and 10 days. In
untreated cultures of cartilage tissue, LPS was not
detected (Figure 1A). In contrast to this, in high-density
cultures treated with LPS, the presence of LPS was sig-
nificantly increased in a time-dependent manner, as
shown by immunoblotting assay (Figure 1A).
To visualize the presence, localization and the interac-
tion with the ECM compound in cartilage tissue, we per-
formed immunoelectron microscopy. After 7 days of
solitary cultivation in high-density cultures, co-cultivation
with LPS (100 ng/ml) for 12 h was performed (Figure
1B-C). High-density cultures show typical cartilaginous
tissue with chondrocytes and appropriate matrix had
developed. Labeling with LPS antibodies revealed the
gold particles to be quite irregularly distributed in the
matrix, formed clusters and were concentrated predomi-
nantly at collagen fibrils in the matrix (Figure 1B). To
determine whether antibodies with the capacity to block
certain binding epitopes on the collagen matrix, could
have any effect on LPS accumulation on the collagen
fibers, after 7 days of solitary cultivation in high-density
cultures, preincubation with anti-collagen type II (100
ng/ml) or with 100 µl/ml control rabbit IgG for 24 h and
then incubation with LPS (100 ng/ml) for 12 h were per-
formed. The collagen type II antibodies were found to
significantly reduce the binding of LPS to collagen type II
compared with LPS treatment alone, which indicates the
involvement of LPS binding to certain epitopes on the
collagen fibers (Figure 1C). In contrast to this, treatment
with control rabbit IgG alone showed abundant accumu-
lation of LPS on the collagen fibers in the matrix (1D).
BMS-345541 or/and wortmannin suppress LPS-induced
degenerative features and apoptosis in chondrocytes and
promote differentiation of LPS-treated chondrocytes in
high-density culture
Our group has previously reported that high-density cul-
ture promotes chondrocyte differentiation since it sup-
ports cell-cell interactions necessary for adequate matrix
formation [32,38]. High-density cultures were prepared
from chondrocytes of monolayer passages 3 and culti-
vated for 7 days and prepared for transmission electron
microscopy. After 7 days in high-density cultures, pri-
mary human chondrocytes showed well-developed carti-
lage nodules with viable cells and well-developed and
organized cell organelles, such as rER, mitochondria,
glycogen granules, free cytoplasmic ribosomes, Golgi
apparatus. The cells were embedded in an extensive fine
fibrillar matrix tightly attached to the cytoplasmic mem-
brane (Figure 2, panel a).
LPS treatment (100 ng/ml) resulted in cell lysis, degen-
erative and apoptotic features including formation of
dense materials in nuclei, formation of blebs at the cell
surface, formation of apoptotic bodies and degeneration
of ECM structure (Figure 2, panel b). After longer incu-
bation periods (10 to 14 days), more severe features of
cellular degeneration such as cell lysis, extensive matrix
breakdown and some characteristic features of apoptotic
cell death (Figure 2, panels c and d) were seen.
We tested whether BMS-345541 or/and wortmannin
can modulate LPS-induced lysis and apoptosis of chon-
drocytes in high-density culture. In contrast to LPS treat-
ment alone, pretreatment with either BMS-345541
(5 mM, specific inhibitor of the IKKb) (Figure 2, panels
e-g) or wortmannin (20 nM, a blocker of PI-3K signaling)
(Figure 2, panels h-j) alone or in combination BMS-
345541 and wortmannin (5 mM and 20 nM) (Figure 2,
panels k-m) significantly reduced the cytotoxic and
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apoptotic effects of LPS. This demonstrates that BMS-
345541 and wortmannin inhibit the cytotoxic and apop-
totic effects induced by LPS in chondrocytes. Interest-
ingly, co-treatment of the chondrocytes with both
blockers inhibited these effects more than each agent by
itself. Taken together, these findings suggest that the NF-
B and PI-3K signaling pathways play (at least in part)
an important role in the destructive effects of LPS in
chondrocytes.
BMS-345541 or/and wortmannin suppress LPS-induced NF-
B-dependent proinflammatory, proapoptotic and matrix-
degrading gene products in chondrocytes
Further, we examined whether BMS-345541 or/and
wortmannin can modulate the activation of LPS-induced
NF-B-regulated gene products involved in the inflam-
mation and degradation processes in cartilage tissue. It
has been previously reported that inflammatory agents
activate COX-2, MMP-9, MMP-13 and caspase-3
through the NF-B signaling pathway [29]. COX-2 is an
enzyme that catalyzes the production of prostaglandin
E2 (PGE2) from arachidonic acid, which is an important
inflammatory mediator that has been linked to the
pathogenesis of RA and OA [39]. MMPs play an impor-
tant role in the pathogenesis of RA and OA by promot-
ing angiogenesis in the synovial joint and facilitating
infiltration of inflammatory cells in the synovial joint by
virtue of its property to degrade extracellular matrix
[40]. Hence, primary human chondrocytes cultured with
or without pretreatment with BMS-345541 or/and wort-
mannin were examined for LPS-induced gene products
by western blot analysis using specific antibodies (Figure
3). Treatment with LPS alone (100 ng/ml) induced the
expression of COX-2, MMP-9, MMP-13, and cleavage
of caspase-3 in a time-dependent manner (Figure 3A-D,
panel 1). In contrast to this, pretreatment with BMS-
Figure 1 Presence of LPS in the extracellular matrix in cartilage tissue. (A) Primary human chondrocytes (1 × 106 cells) were cultured in
high-density culture with lipopolysaccharides (LPS) (100 ng/ml) or without LPS (Co) for different times. Whole-cell extracts were prepared, and
cell lysates were resolved by SDS-PAGE, electrotransferred to nitrocellulose membrane, and then probed for LPS expression by western blot
analysis using antibodies to this protein. b-Actin served as an internal control. LPS control peptide (Co Pep) was used as a control. M = marker
for molecular weights. (B) Primary human chondrocytes (Ch) (1 × 106 cells) were cultured for 7 days in high-density culture and then incubated
with LPS (100 ng/ml) for 12 h before evaluation by immunoelectron microscopy. Secondary gold particle-labeled antibody was observed directly
on the collagen bundles or clustered (arrows) together indicating the existence of LPS between the mesh of the collagen fibers in the
extracellular matrix (ECM). (C-D) Primary human chondrocytes (Ch) (1 × 106 cells) were cultured for 7 days in high-density culture, and then first
preincubated with anti-collagen type II (100 ng/ml) (C) or control rabbit IgG (100 µl/ml) (D) for 24 h and followed by incubation with LPS (100
ng/ml) for 12 h before evaluation with immunoelectron microscopy. Opposite to preincubated cultures with control rabbit IgG, only a very small
amount of secondary gold particle-labeled antibodies was observed on the collagen bundles or clustered (arrows) in the extracellular matrix
(ECM) in preincubated cultures with anti-collagen type II. Magnification x35,000; bar, 0.25 µm.
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Figure 2 LPS induced cellular and matrix degradation and apoptosis in cartilage tissue. Primary human chondrocytes were either left
untreated (a) or were treated with 100 ng/ml lipopolysaccharides (LPS) (b-d), pretreated with BMS-345541 (5 mM) (e-g), wortmannin (20 nM)
(h-j) followed by LPS treatment, or pretreated in combination with BMS-345541 and wortmannin (5 mM and 20 nM) (k-m) for 12 h and then
stimulated with LPS for another 24 h. The cells were transferred to high-density culture for 14 days. Ultrastructural morphology was evaluated by
electron microscopy. Control cultures of chondrocytes showed well-developed chondrocytes (Ch) embedded in a well-developed extracellular
matrix (ECM) (a). Treatment with LPS resulted in matrix breakdown and cell lysis and apoptosis (arrows) (b-d). Pretreatment with BMS-345541
alone (e-g), with wortmannin alone (h-j) or in combination with BMS and wortmannin (k-m) resulted in a marked improvement of chondrocyte
phenotype and the formation of cartilage nodules. The formation of a dense extracellular matrix (ECM) surrounding well-developed
chondrocytes (Ch) was observed. Magnification x5000; bar, 1 µm.
Figure 3 Effects of BMS-345541 or/and wortmannin on the LPS-induced proinflammatory and apoptotic signaling in human
chondrocytes. Primary human chondrocytes in monolayer cultures were either left untreated or stimulated with 100 ng/ml lipopolysaccharides
(LPS), prestimulated with 5 mM BMS-345541, with 20 nM wortmannin or a combination of both inhibitors, BMS-345541 and wortmannin (5 mM
and 20 nM) for 12 h and then treated with 100 ng/ml LPS for the indicated times. Whole-cell extracts were fractionated (500 ng protein per
lane) on SDS-PAGE and examined by western blot analysis using anti-matrix metalloproteinase (MMP)-9 (A), -MMP-13 (B), -cyclooxygenase-2
(Cox-2) (C) and anti-cleaved caspase-3 (D). The results shown are representative of three independent experiments. Housekeeping protein b-
actin served as a loading control.
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345541 or wortmannin significantly inhibited the
expression of the mentioned genes and cleavage of cas-
pase-3 (Figure 3A-D, panel 2, 3). Combinational pre-
treatment of the inhibitors was effective in inhibition of
these proinflammatory proteins in the same manner in
chondrocytes (Figure 3A-D, panel 4).
Suppressive effect of BMS-345541 or/and wortmannin on
LPS-induced phosphorylation and translocation of NFB-
p65 in nuclear extracts of chondrocytes in a dose- and
time-dependent manner
First, the optimum dose and time of exposure to LPS
required to induce NF-B activation has been deter-
mined (data not shown). To evaluate whether LPS
induces activation of NF-B, nuclear protein extracts of
serum-starved human chondrocytes were probed for the
phosphorylated p65 NF-B subunit after treatment with
the indicated concentrations of LPS for 30 min (Figure
4A). As indicated by western blotting analysis, LPS
induced NF-B activation in a dose-dependent manner
(Figure 4A). We next investigated whether activation of
NF-B by LPS is also time dependent. For this, primary
human chondrocytes were incubated with 100 ng/ml
LPS for the indicated times. Western blotting results
showed that activation of NF-B by LPS was also found
to be time-dependent (Figure 4B). Taken together, these
findings indicate that the activation and translocation of
NF-B by LPS is dose- as well as time-dependent.
We next focused on the mechanistic relationship
between LPS effects and NF-B signaling pathways.
BMS-345541 is a potent and specific IKK inhibitor and
can effectively inhibit NF-B activation induced by
diverse stimuli [41]. Wortmannin is a specific inhibitor
of PI-3K signaling [24]. Therefore, we treated primary
Figure 4 LPS induced the phosphorylation and translocation of p65 and the IKK inhibitor BMS-345541 or PI-3K inhibitor wortmannin
suppressed this in a time- and dose-dependent manner. (A-B) Primary human chondrocytes in monolayer culture were either left untreated
(controls), treated with lipopolysaccharides (LPS) (0, 0.1, 1, 10, 100 and 1000 ng/ml) for 30 min (A) or stimulated with 100 ng/ml LPS for the
indicated times (B). Nuclear extracts were prepared and assayed for nuclear factor-B (NF-B) (p65) activation by western blot analysis as
described in Materials and methods. (C-F) Primary human chondrocytes in monolayer cultures were either left alone or pretreated with BMS-
345541 or with wortmannin for the indicated concentrations followed by treatment with 100 ng/ml LPS for 30 min (C and E), or prestimulated
with 5 mM BMS-345541 or with 20 nM wortmannin for 12 h and co-treated with 100 ng/ml LPS for the indicated times (D and F). Nuclear
extracts were prepared and assayed for NF-B (p65) activation by western blot analysis as described in Materials and methods. Synthesis of poly
(ADP-ribose) polymerase (PARP) remained unaffected in nuclear extracts. IKK, IB kinase; PI-3K, phosphatidylinositol 3-kinase.
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chondrocytes with BMS-345541 or/and wortmannin to
determine whether the effects of LPS on chondrocytes
are also associated with an altered activation status of
the IKK-NF-B and PI-3K pathways and whether it
suppressed the destructive effects of LPS. Serum-
starved chondrocytes were pretreated with BMS-
345541 or/and wortmannin and then co-treated with
LPS. As shown in Figure 4, pretreatment with
BMS-345541 or/and wortmannin inhibited the LPS-
induced phosphorylation and translocation of p65 to
the nucleus in a time- and dose-dependent manner
(Figure 4C-F).
BMS-345541 inhibits LPS-induced nuclear translocation of
p65 as revealed by immunofluorescence microscopy
Based on the western blotting results (Figure 4) and to
confirm them, we performed immunocytochemical ana-
lysis. Primary human chondrocytes either served as con-
trols (not treated: Co-IF, without primary antibody,
Figure 5, a-b; not treated: basal co, with primary
Figure 5 BMS-345541 or wortmannin inhibited LPS-induced nuclear translocation of phospho p65 in chondrocytes as demonstrated
by immunofluorescence microscopy. Primary human chondrocyte cultures either served as controls (a-b: without primary antibody; c-d: with
primary antibody) or were treated with lipopolysaccharides (LPS) alone (e-f) or were pre-treated with wortmannin (20 nM) (g-h) or with BMS-
345541 (5 mM) (i-j) for 12 h before co-treatment with LPS (100 ng/ml) for 24 h before immunolabeling with phospho p65 antibodies and
rhodamine-coupled secondary antibodies and counterstained with DAPI to visualize cell nuclei. Images shown are representative of three
independent experiments. Magnification x400; bar, 30 nm.
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antibody, Figure 5, c-d) or were stimulated with BMS-
345541 alone (data not shown), with wortmannin alone
(data not shown) or with 100 ng/ml LPS alone for 12 h
(Figure 5, e-f) or were co-treated with wortmannin
(20 nM) (Figure 5, g-h) or with BMS-345541 (5 mM)
(Figure 5, i-j) for 12 h before treating with LPS (100 ng/
ml) for 24 h before indirect immunolabeling with anti-
phospho p65 antibodies and rhodamine-coupled second-
ary antibodies. Counterstaining was performed with
DAPI to visualize the cell nuclei. Immunofluoroscence
microscopy showed clear and intensive cytoplasmic and
nuclear staining for phospho p65 in primary human
chondrocytes treated with LPS (Figure 5, e-f). In con-
trast to this, co-treatment of chondrocytes with LPS and
BMS-345541 or wortmannin resulted in decreased
nuclear staining of activated phospho p65 and indicated
a decrease in activation of NF-B (Figure 5, g-j). Control
chondrocytes and chondrocytes treated with BMS-
345541 or wortmannin alone (data not shown) showed
only cytoplasmic labeling of phospho p65 (Figure 5,
c-d). These immunomorphological findings were consis-
tent with the NF-B inhibition observed by western
blotting. Images shown are representative of three inde-
pendent experiments.
BMS-345541 or wortmannin inhibits LPS-induced-IBa
degradation and phosphorylation in chondrocytes
BMS-345541 or wortmannin inhibited LPS-induced
activation and translocation of NF-B to the chondro-
cyte nucleus. Therefore, we evaluated the upstream
mechanisms of NF-B activation by LPS in chondro-
cytes. It has been reported that the phosphorylation
and degradation of IBa, the natural blocker of NF-
B, is a prerequisite for the activation of NF-B [42].
To examine whether inhibition of LPS-induced NF-B
activation occurs through inhibition of IBa degrada-
tion, we treated cells with BMS-345541 or wortman-
nin, followed by LPS stimulation and probed them for
IBa activation in the cytoplasm by western blot ana-
lysis. LPS induced IBa degradation in control cells as
early as 20 min (Figure 6A, I) but in co-treated cul-
tures the degradation of IBa was not evident (Figure
6A, I). These results indicate that LPS induces IBa
degradation by acting at an upstream step to NF-B
activation. Furthermore, LPS-induced IBa phosphory-
lation was almost completely blocked by BMS-345541
or wortmannin (Figure 6A, II). These results indicate
that BMS-345541 or wortmannin inhibits both LPS-
induced IBa degradation and phosphorylation. Data
shown are representative of three independent experi-
ments. Taken together, these results suggest that BMS-
345541 or wortmannin block LPS-induced IBa
degradation.
Effect of BMS-345541 or wortmannin on LPS-induced
activation of IKK in chondrocytes in monolayer cultures
IKK is required for phosphorylation of IBa [42]. To
determine whether BMS-345541, the specific inhibitor
of IKKb [41] or wortmannin a specific inhibitor of PI-
3K signaling [24] can inhibit the NF-B pathway, we
tested the effect of BMS-345541 or wortmannin on
LPS-induced IKK activation, which is required for LPS-
induced phosphorylation of IBa. Immune complex
kinase assays showed that LPS induced the activation of
IKK in a time-dependent manner. In contrast to this,
pretreatment of chondrocytes with BMS-345541 or
wortmannin followed by stimulation with LPS resulted
in an inhibition of LPS-induced effects on the activation
of IKK (Figure 6B, I). LPS, BMS-345541 or wortmannin
had no direct effect on the expression of IKK-a or IKK-
b proteins (Figure 6B, II, III).
The effect of wortmannin (PI-3K inhibitor) on LPS-induced
phosphorylation of PI-3K/Akt in chondrocytes
It has been reported that the phosphatidylinositol 3-
kinase phosphorylation of endogenous Akt pathway is
required for the activation of NF-B, as an upstream
protein kinase, and wortmannin is a specific inhibitor of
PI-3K signaling [24]. Next, therefore, we determined
whether LPS induces phosphorylation of PI-3K/Akt in
chondrocytes. As indicated by western blotting using an
antibody specific for phosphorylated Akt, LPS induced
Akt phosphorylation greatly in a dose-dependent man-
ner (Figure 7A). Further, we examined whether activa-
tion of Akt by LPS is also time dependent. Primary
human chondrocytes were incubated with 100 ng/ml
LPS for the indicated times. Western blotting showed
that activation of Akt by LPS was also found to be time
dependent (Figure 7B).
To examine the role of the PI-3K/Akt signaling path-
way in regulating LPS-mediated NF-B activation, the
level of Akt phosphorylation protein was analyzed using
selective kinase inhibitors. Chondrocytes were pretreated
with inhibitors of PI-3K (wortmannin), respectively for 1
h, and then co-treated with 100 ng/ml LPS for 1 h. As
shown in Figure 7C-D, the activation of Akt (upstream
protein kinase B) in chondrocytes was significantly
reduced by preincubation with wortmannin in a time-
and dose-dependent manner. These results further sug-
gest that LPS-induced NF-B activation in chondrocytes,
at least in part, is regulated through the PI-3K/Akt sig-
naling pathway.
LPS induces the expression of and physically binds to
TLR4 in human chondrocytes
To better understand the mechanism whereby LPS
induces degradation of cartilage and ECM, activation of
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p65 and PI-3K and degradation of IBa, we examined
the activation and binding of TLR4 with LPS on human
chondrocytes following LPS treatment. Indeed, it has
been reported that LPS is the primary ligand of the
Toll-like receptor 4 (TLR4) [18].
TLR4 expression is low in normal untreated human
chondrocytes (Figure 8A). We asked whether TLR4
expression is increased and characterized a subset of
LPS in chondrocytes. To address this question, we trea-
ted the chondrocytes in monolayer cultures with differ-
ent concentration of LPS (10 or 100 ng/ml) for 12 h or
left them untreated and examined them with immuno-
fluorescent staining for TLR4. As shown in Figure 8A:
a-d, the expression of TLR4 is clearly increased by LPS
and this was dose dependent. These data suggest that
LPS induces TLR4 expression, as its receptor in
inflamed chondrocytes. Therefore, we further examined
the effect of LPS on TLR4 and LPS-induced LRP-TLR4
association by a co-immunoprecipitation assay. Primary
human chondrocytes were treated with 100 ng/ml LPS
for 4 h or left untreated (c). After 4 h of incubation, the
media were replaced with the regular medium, lysed and
then co-immunoprecipitation assays were performed.
After immunoprecipitation with anti-LPS antibodies, the
samples were probed by immunoblotting with anti-TLR4.
The results indicate that LPS was co-immunoprecipitated
by anti-TLR4 antiserum but not by control cultures
(Figure 8B). As a control, the immunoprecipitation by a
control IgG did not result in precipitation of TLR4 (not
shown). Taken together, these results indicate that LPS-
TLR4 complex formation is one of the major pathways,
which activates the NF-B and PI-3K pathways in
chondrocytes.
Discussion
The data presented in this manuscript provides evi-
dence to support the idea that endotoxins distributed
in the cartilage matrix form clusters and concentrate
predominantly at the frayed end of collagen fibrils in
the matrix (procollagen-endotoxin complexes, PEC),
Figure 6 Effects of BMS-345541 and wortmannin on LPS signalling in chondrocytes. (A) Effects of BMS-345541 or wortmannin on LPS-
induced IB-a phosphorylation and degradation in chondrocytes in monolayer cultures. Primary human chondrocytes in monolayer
culture were either stimulated with 100 ng/ml lipopolysaccharides (LPS) or prestimulated with 5 mM BMS-345541 or with 20 nM wortmannin for
12 h followed by LPS treatment (100 ng/ml) for the indicated times. Cytoplasmic extracts were prepared, fractionated (500 ng protein per lane)
on 10% SDS-PAGE and electrotransferred onto nitrocellulose membranes. Western blot analysis was performed with anti-phospho-specific-IB-a
(II), anti-IB-a (I) and anti-b-actin (II, control). The results shown are representative of three independent experiments. (B) Effects of BMS-
345541 or wortmannin on LPS-induced IKK activation in chondrocytes in monolayer cultures. Primary human chondrocytes in monolayer
culture were either stimulated with 100 ng/ml LPS or prestimulated with 5 mM BMS-345541 or with 20 nM wortmannin for 12 h followed by
treatment with 100 ng/ml LPS for the indicated times. Whole-cell extracts were immunoprecipitated with an antibody against IkB kinase (IKK)
and then analyzed by an immune complex kinase assay as described in Materials and methods. To examine the effect of LPS, BMS-345541 or
wortmannin on the level of activation of IKK proteins, whole-cell extracts were fractionated (500 ng protein per lane) on SDS-PAGE and
examined by western blot analysis using anti-phospho-specific-IB-a and anti-IB-b (I). LPS, BMS-345541 or wortmannin had no direct effect on
the expression of IKK-a or IKK-b proteins (II, III). The results shown are representative of three independent experiments.
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suggesting that collagens and the ECM may act as a
reservoir for endotoxins.
We have made the following novel observations: (I) as
demonstrated by immunoelectron microscopy and wes-
tern blot analysis, we showed the presence of LPS in
cartilage matrix bound to the collagen fibrils and anti-
collagen type II significantly reduced this interaction.
(II) LPS-induced massive cartilage matrix break down
and chondrocytes apoptosis is blocked in part by BMS-
345541 (IKK-inhibitor), and was completely inhibited by
the combinational pretreatment of BMS-345541 and
wortmannin (a specific inhibitor of the PI-3K/Akt path-
way), suggesting that NF-B and PI-3K pathways are
involved in LPS-induced cartilage degradation. (III)
Wortmannin potentiates the anti-inflammatory and
anti-apoptotic effects of BMS-345541 on LPS-stimulated
chondrocytes, and this correlates with downregulation
of NF-B-specific gene products that are known to
mediate inflammation, degradation and apoptosis of
chondrocytes in OA and RA. (IV) LPS induced
activation and translocation of p65 from the cytoplasm
to the nucleus in a dose- and time-dependent manner
and these effects were inhibited by BMS-345541 or/and
wortmannin. (V) Suppression of NF-B activation by
BMS-345541 or/and wortmannin is due to inhibition of
LPS-induced IKK activation, which led to inhibition of
IBa phosphorylation and degradation and suppression
of p65 phosphorylation and its translocation to the
nucleus. (VI) LPS induced the PI-3K/Akt pathway and
this was inhibited by wortmannin. (VII) Finally, LPS sti-
mulated TLR4 and, associated with TLR4, initiated NF-
B and PI-3K activation pathways.
A number of studies have reported that the inhabitants
of buildings with dampness through, for example, water
damage have an increased risk of RA [19-21]. A connec-
tion between microbial infestation of buildings after water
damage and RA manifestation in inhabitants has been
observed, where symptoms of RA decreased in patients
after removing damp walls [19]. Previous studies from our
group reported that in primary isolated chondrocytes,
Figure 7 LPS induced PI-3K/Akt activation and PI-3K inhibitor (wortmannin) suppressed this in a time- and dose-dependent manner.
(A-B) Primary human chondrocytes in monolayer culture were either left untreated (controls), treated with lipopolysaccharides (LPS) (0, 0.1, 1, 10,
100 and 1000 ng/ml) for 50 min or stimulated with 100 ng/ml LPS for the indicated times. Nuclear extracts were prepared and assayed for Akt
activation by western blotting as described in Materials and methods. (C-D) Primary human chondrocytes in monolayer cultures were either left
untreated or were prestimulated with wortmannin for the indicated concentrations and treated with 100 ng/ml LPS for 50 min, or prestimulated
with 20 nM wortmannin for 12 h followed by co-treatment with 100 ng/ml LPS for the indicated times. Nuclear extracts were prepared and
assayed for Akt activation by western blot analysis as described in Materials and methods. Housekeeping protein b-actin served as a loading
control and remained unaffected. PI-3K, phosphatidylinositol 3-kinase.
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bacterial toxins taken from damp walls in buildings with
water damage dose-dependently increased MMPs produc-
tion and suppressed collagen type II production in vitro
[19]. Therefore, we assumed that very fine particles, or
LPS, are inhaled by the inhabitants and are partly trans-
ported to the joints/cartilage through circulation.
We hypothesized that LPS may interfere directly with
the mechanisms for the synthesis and assembly of col-
lagen fibers (Figure 9). Therefore, to perform new
experiments with a well-defined compound, we chose
LPS from E.coli. If LPS from E.coli has the same effects
as the environmental LPS, it seems reasonable that the
model we have developed will be valid for studying the
effects of environmental noxa and systemic mediators of
chronic bacterial inflammation for example peridontitis.
In fact, binding of LPS to collagen type II can signifi-
cantly be reduced by antibodies against collagen type II.
This is compelling evidence for involvement of LPS
binding to certain epitopes on the collagen fibers, sug-
gesting the potential role of collagens as a reservoir for
endotoxins. It is most likely that this binding between
LPS and collagen type II influences cellular behavior
(differentiation, cell shape, secretion products) and intra-
cellular signaling. However, the molecular mechanism of
LPS-collagen binding and thus control of ECM synthesis
is at present only poorly understood. Interestingly, it has
Figure 8 LPS induced TLR4 expression and associated with TLR4 in human chondrocytes. (A) Primary human chondrocytes were either
left untreated (b, basal Co) or were treated with 10 ng/ml (c) or 100 ng/ml lipopolysaccharides (LPS) (d) for 12 h, then were immunostained
with anti-Toll-like receptor 4 (TLR4) (red) and counterstained with DAPI (blue). Control, in which primary antibodies were replaced with control
rabbit IgG (a). Results are representative of three experiments using human chondrocytes. Magnification x400; bar, 30 nm. (B) Lysates prepared
from human chondrocytes exposed to LPS (100 ng/ml) or untreated (c) (negative control) were incubated with anti-LPS. Immunoprecipitates
were analyzed by western blotting with anti-TLR4. Presence of band of the correct size (approximately 100 kDa) corresponding to chondrocytes
treated with LPS confirms the binding of LPS to TLR4. The original samples were probed with an antibody to anti-TLR4. Data shown are
representative of three independent experiments. IgH: immunglobulin heavy chain.
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been already hypothesized that in obese patients with
metabolic endotoxemia, that is high blood levels of LPS,
caused by an impaired gastric mucosa may strongly con-
tribute to the formation of OA [43].
The procollagens contain telopeptides at the C- and
N-terminal ends, which have to be cleaved by specific
catabolic enzymes (N- and C-proteinase) to render the
mature tropocollagen molecule, which is then released
from the cell [44]. The procollagen have frayed ends,
which have a remarkable similarity to the ends of some
Toll-like receptors (TLRs, specifically TLR4) [45], which
are localized in the cell membrane of immune cells,
especially macrophages [46]. We previously hypothe-
sized that bacterial structures such as endotoxins bind
to the end of procollagen in the cartilage ECM [19].
Thus, a stable procollagen-endotoxin complex (PEC)
may form and through that collagen synthesis in chon-
drocytes may be disrupted.
We found that, BMS-345541, an inhibitor of NF-B
activation, blocked a part of the LPS-induced degradation
of ECM and apoptosis, but this was completely inhibited
by the combination of BMS-345541 and wortmannin,
suggesting that NF-B and PI-3K pathways are involved
in LPS-induced cartilage degradation. We have also
shown that LPS stimulates the expression of several pro-
teins that are regulated by NF-B, including proapoptotic
protein caspase-3, the matrix-degrading MMPs, as well
as the inflammatory enzyme COX-2 and this was blocked
by BMS-345541 or/and wortmannin. Western blot analy-
sis showed that BMS-345541 downregulated the activa-
tion of NF-B by the inhibition of IBa and IKK,
suggesting the involvement of NF-B in regulation of
LPS-induced proapoptotic and degradative pathways in
cartilage. These results support previous reports that
have shown that LPS induces activation of NF-kB and
downstream activities in normal or osteoarthritic mam-
malian chondrocytes [47-54]. In contrast to these studies,
in this paper, we are showing for the first time that LPS
stimulate the PI-3K/Akt signaling pathway in chondro-
cytes, which was inhibited by wortmannin, a specific
Figure 9 Inhibitory effects of BMS-345541 or/and wortmannin on LPS-induced NF-B/PI-3K and apoptosis in primary human
chondrocytes in vitro. Lipopolysaccharides (LPS)-induced disruption of cartilage may be induced through LPS complex formation with collagen
II fibrils and through LPS/Toll-like receptor 4 (TLR4) association. Anti-collagen type II significantly reduced these procollagen-endotoxin
complexes. Functional association with TLR4 leads to activation of intracellular downstream signaling pathway NF-B, nuclear factor-B (NF-B)/
PI-3K, phosphatidylinositol 3-kinase (PI-3K) inducing upregulation of matrix-degrading enzymes, inflammation and apoptosis. Culturing with
specific inhibitors wortmannin (for PI-3K/AKT) and BMS-345541 (for IB kinases (IKKs)) suppresses LPS-induced inflammatory response indicating
the potential for new medical approaches.
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inhibitor of the PI-3K/Akt pathway. This is also consis-
tent with studies that have shown that NF-B activation
requires the PI-3K/Akt signaling pathway [55,56]. These
findings explain, at least in part, the inflammatory and
apoptotic effects of LPS in chondrocytes.
It has been reported that kinase Akt (protein kinase B)
functions upstream of IKK [57]. Furthermore, previous
studies have shown the inhibition of NF-B to the DNA
binding through the blocking of IBa phosphorylation
by the PI-3K/Akt pathway in various cell types
[24,58-60]. However, downregulation of upstream sig-
naling proteins, such as PI-3K/Akt by wortmannin, may
be involved in LPS-mediated activation of NF-B in
chondrocytes.
We showed that LPS stimulated NF-B/PI-3K path-
ways and these were suppressed by specific NF-B/PI-
3K inhibitors. Therefore, we approached to investigate
whether LPS signaling acts through TLR4 (the primary
receptor for LPS), in human chondrocytes. Indeed, we
could demonstrate that LPS induced TLR4 expression
on the surface of chondrocytes in a dose-dependent
manner, which is consistent with a previous report
[16,18]. Interestingly, immunoprecipitation assay and
western blotting demonstrated functional and physical
interactions between LPS and TLR4 in chondrocytes,
suggesting that this complex initiates NF-B and PI-3K
activation pathways. Similar to our findings, recent stu-
dies in adipocytes have reported that LPS actively bind
to adipocyte-expressed TLR4 inducing inflammation sig-
naling in adipocytes [61,62].
Conclusions
Our results suggest that LPS physically interact with col-
lagen type II in the extracellular matrix and anti-col-
lagen type II significantly reduced this interaction.
Further, our study demonstrates, for the first time, that
the blockade of LPS-induced activation of NF-B and
PI-3K pathways by specific inhibitors (BMS-345541 or
wortmannin) explains the observed effects of LPS/TLR4
association on downstream proinflammatory responses,
including the inhibition of cartilage ECM breakdown,
inflammation and apoptosis in chondrocytes (Figure 9).
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